You are here

PloS one DOI:10.1371/journal.pone.0090485

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.

Publication TypeJournal Article
Year of Publication2014
AuthorsLi, JZ, Chapman, B, Charlebois, P, Hofmann, O, Weiner, B, Porter, AJ, Samuel, R, Vardhanabhuti, S, Zheng, L, Eron, J, Taiwo, B, Zody, MC, Henn, MR, Kuritzkes, DR, Hide, W, ACTG A5262 Study, T, Wilson, CC, Berzins, BI, Acosta, EP, Bastow, B, Kim, PS, Read, SW, Janik, J, Meres, DS, Lederman, MM, Mong-Kryspin, L, Shaw, KE, Zimmerman, LG, Leavitt, R, De La Rosa, G, Jennings, A
JournalPloS one
Date Published2014/01/01

The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina and 454 for the detection of HIV-1 raltegravir-resistant MVs.